Evidence map›Paper›PMID 31022428›Full record

ArticleExperimental hematology2019

Acute myeloid leukemia driven by the CALM-AF10 fusion gene is dependent on BMI1.

Karina Barbosa, Anagha Deshpande, Bo-Rui Chen, Anwesha Ghosh, Younguk Sun, Sayantanee Dutta, Marla Weetall, Jesse Dixon, Scott A Armstrong, Stefan K Bohlander and 1 more

Open access · greenAbstract read
In one paragraph

Article in Experimental hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Zebrafish models of acute leukemias: Current models and future directions.Wiley interdisciplinary reviews. Developmental biology · 2021
    Review
  10. Article
  11. Article
  12. Article
  13. Genome-Wide DNA Methylation Profiles in Community Members Exposed to the World Trade Center Disaster.International journal of environmental research and public health · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 3 countries.

Karina BarbosaTumor Initiation and Maintenance Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.
Anagha DeshpandeTumor Initiation and Maintenance Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.
Bo-Rui ChenTumor Initiation and Maintenance Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.
Anwesha GhoshTumor Initiation and Maintenance Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.
Younguk SunTumor Initiation and Maintenance Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA.
Sayantanee DuttaDepartment of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Marla WeetallPTC Therapeutics, South Plainfield, NJ.
Jesse DixonPeptide Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA.
Scott A ArmstrongDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.
Stefan K BohlanderDepartment of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand. Electronic address: s.bohlander@auckland.ac.nz.
Aniruddha J DeshpandeTumor Initiation and Maintenance Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA. Electronic address: adeshpande@sbpdiscovery.org.
Sanford Burnham Prebys Medical Discovery Institute · USDiscovery Institute · USDana-Farber Cancer Institute · USLMU Klinikum · DENational Cancer Institute · USPTC Therapeutics (United States) · USSalk Institute for Biological Studies · USUniversity of Auckland · NZ

Funding

Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Michael Jackson · 1985 to 2026
$107.2M
The role of AF10 in normal and leukemic hematopoiesisR00CA154880 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI DESHPANDE, ANIRUDDHA J. · 2015 to 2017
$747k
NCI NIH HHS P30 CA030199NCI NIH HHS R00 CA154880
6 · The paper itself

Abstract

A subset of acute myeloid and lymphoid leukemia cases harbor a t(10;11)(p13;q14) translocation resulting in the CALM-AF10 fusion gene. Standard chemotherapeutic strategies are often ineffective in treating patients with CALM-AF10 fusions. Hence, there is an urgent need to identify molecular pathways dysregulated in CALM-AF10-positive leukemias which may lay the foundation for novel targeted therapies. Here we demonstrate that the Polycomb Repressive Complex 1 gene BMI1 is consistently overexpressed in adult and pediatric CALM-AF10-positive leukemias. We demonstrate that genetic Bmi1 depletion abrogates CALM-AF10-mediated transformation of murine hematopoietic stem and progenitor cells (HSPCs). Furthermore, CALM-AF10-positive murine and human AML cells are sensitive to the small-molecule BMI1 inhibitor PTC-209 as well as to PTC-596, a compound in clinical development that has been shown to result in downstream degradation of BMI1 protein. PTC-596 significantly prolongs survival of mice injected with a human CALM-AF10 cell line in a xenograft assay. In summary, these results validate BMI1 as a bona fide candidate for therapeutic targeting in AML with CALM-AF10 rearrangements.

Indexed as

AnimalsHeterocyclic Compounds, 2-RingHumansLeukemia, Myeloid, AcuteMiceMice, TransgenicNeoplasms, ExperimentalOncogene Proteins, FusionPolycomb Repressive Complex 1Proto-Oncogene ProteinsThiazolesU937 CellsXenograft Model Antitumor AssaysAF10-CALM fusion protein, humanBMI1 protein, humanBmi1 protein, mouseHeterocyclic Compounds, 2-RingOncogene Proteins, FusionPolycomb Repressive Complex 1Proto-Oncogene ProteinsPTC-209Thiazoles

Identifiers

PMID31022428
PMCPMC10586237
OpenAlexW2952034850

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.